The feasibility of additional CD19-targeted cellular therapy in relapsed/refractory B-ALL with re-emergence of CD19 antigen after prior CD19-negative relapse.
Vaibhav AgrawalAmandeep SalhotraJoo SongZhaohui GuAnthony S SteinGuido MarcucciStephen J FormanVinod A PullarkatIbrahim AldossPublished in: American journal of hematology (2022)